|
PARIS, Jan. 22, 2026 /PRNewswire/ -- Faithful to its pioneering spirit since its creation in 1954, Clarins continues its commitment to customer-centric innovative beauty. In 2025, the brand takes a new step by launching the AI Skin Observer, its latest technological gem dedicated to advanced skin analysis.
This new cutting-edge device is currently being deployed in 20 stores worldwide, including John Lewis Oxford Street in London, Printemps Haussmann in Paris, Clarins boutique in Dubai Hills, La Rinascente in Milan, Clarins boutique & spa in Shanghai Jing An Kerry Center, and Macy's Herald Square in New York.
A simplified web version is also available online on Clarins website in several countries including the US (http://www.clarinsusa.com), the UK (https://www.clarins.co.uk) and France (https://www.clarins.fr).
A true milestone in the beauty industry.
AI serving human expertise: leveraging both biophysical sensors and face pictures with multiple lighting modes, the AI Skin Observer analyzes up to 22 skin parameters, hence providing unique information about the skin, enriching and refining the expertise of the advice offered in-store.
Perfectly integrated in the retail store selling ceremony: taking the form of a mirror, the AI Skin Observer is perfectly integrated on existing consultation tables, a central element in each Clarins point of sale.
A new release from Clarins Beauty Tech.
Latest launch of an ambitious R&D program dedicated to Clarins customer experience innovation, the AI Skin Observer, developed with the support of an ecosystem of start-ups, is the result of years of fundamental research into skin analysis by the Clarins laboratory and the Group's progress in AI and imaging, particularly within its Beauty Tech division.
A true extension of the manual Skin Check, the AI Skin Observer represents a natural evolution for Clarins brand which has never ceased to combine science, nature and human expertise, and fully embraces Beauty Tech.
The AI Skin Observer is the latest release from Clarins Group Beauty Tech division, following the Lip Oil Factory – enabling on-demand customization of iconic Clarins Lip Oil – and MyBlend LED mask.
Clarins brand General Manager, Katalin Berenyi: "The AI Skin Observer is designed to fit perfectly into our retail space. Through its ease of use, it allows beauty advisors to remain focused on listening to the client and her needs. It extends their expertise by revealing dimensions invisible to the eye, thanks to algorithms leveraging years of research from Clarins laboratory. By combining AI, beauty tech with human touch, beauty consultations are enhanced."
Clarins group Chief Digital, IT & Business Support Officer, Laurent Malaveille: " We are very proud of the AI Skin Observer, the latest Beauty Tech release from our innovation lab, and excited by the enthusiastic feedback from both our beauty consultants and the first customers who tested this new service."
About Clarins
Founded in Paris in 1954 by Jacques Courtin, Clarins is a family-owned global beauty group that has been innovating for more than 70 years to advance responsible beauty. As a result of continuous research, its plant-based products — formulated and manufactured in France — are sold in over 150 countries through 20,000 points of sale. With nearly 95% of sales generated internationally, Clarins is the No. 1* premium skincare brand in Europe and a leading global player in beauty (skincare and make-up), spa, and wellness. The Group has also developed the brand myBlend, built on the concept of holistic beauty, combining targeted skincare, nutri-cosmetics, and beauty tech. Clarins counts more than 8,000 employees across its Paris headquarters, 28 subsidiaries worldwide, two R&D laboratories, and two industrial sites in France. The Group is jointly led by Jonathan Zrihen, President & CEO, together with Dr. Olivier Courtin and his niece Virginie Courtin, representing the second and third generations of the founding family. Guided by its raison d'être — "Making life more beautiful, passing on a more beautiful planet" — Clarins is committed to sustainable innovation, with over 80% of ingredients of natural origin and a wide range of initiatives to protect nature and care for people. https://www.groupeclarins.com/
*Source: NPD BeautyTrends®, Europe 5 (France, Germany, United Kingdom, Italy, Spain), luxury Skin Care market (products sold in perfumeries and department stores), value sales (€), for the period 3rd January 2022 to 1st January 2023.
Press contacts
France
Image Sept – Marie Artzner - Anne Auchatraire – Caroline Simon - clarins@image7.fr - +33 1 53 70 74 70
USA
Melissa Reidhead – melissa.reidhead@clarins.com and Lucas Petry – lucas.petry@clarins.com
UK
Shoshana Gillis – shoshana.gillis@clarins.com – +44 207 307 6792
China
Derek Hu – derek.hu@clarins.com – +86 186 0166 7400
Italy
Francesca Silva – Francesca.Silva@clarins.com and F.A Studio - f.andreuzzi@fa-studio.eu - c.gorla@fa-studio.eu
UAE
Jala Dia – Jala.Dia@clarins.com
PARIS, Jan. 22, 2026 /PRNewswire/ -- Faithful to its pioneering spirit since its creation in 1954, Clarins continues its commitment to customer-centric innovative beauty. In 2025, the brand takes a new step by launching the AI Skin Observer, its latest technological gem dedicated to advanced skin analysis.
This new cutting-edge device is currently being deployed in 20 stores worldwide, including John Lewis Oxford Street in London, Printemps Haussmann in Paris, Clarins boutique in Dubai Hills, La Rinascente in Milan, Clarins boutique & spa in Shanghai Jing An Kerry Center, and Macy's Herald Square in New York.
A simplified web version is also available online on Clarins website in several countries including the US (http://www.clarinsusa.com), the UK (https://www.clarins.co.uk) and France (https://www.clarins.fr).
A true milestone in the beauty industry.
AI serving human expertise: leveraging both biophysical sensors and face pictures with multiple lighting modes, the AI Skin Observer analyzes up to 22 skin parameters, hence providing unique information about the skin, enriching and refining the expertise of the advice offered in-store.
Perfectly integrated in the retail store selling ceremony: taking the form of a mirror, the AI Skin Observer is perfectly integrated on existing consultation tables, a central element in each Clarins point of sale.
A new release from Clarins Beauty Tech.
Latest launch of an ambitious R&D program dedicated to Clarins customer experience innovation, the AI Skin Observer, developed with the support of an ecosystem of start-ups, is the result of years of fundamental research into skin analysis by the Clarins laboratory and the Group's progress in AI and imaging, particularly within its Beauty Tech division.
A true extension of the manual Skin Check, the AI Skin Observer represents a natural evolution for Clarins brand which has never ceased to combine science, nature and human expertise, and fully embraces Beauty Tech.
The AI Skin Observer is the latest release from Clarins Group Beauty Tech division, following the Lip Oil Factory – enabling on-demand customization of iconic Clarins Lip Oil – and MyBlend LED mask.
Clarins brand General Manager, Katalin Berenyi: "The AI Skin Observer is designed to fit perfectly into our retail space. Through its ease of use, it allows beauty advisors to remain focused on listening to the client and her needs. It extends their expertise by revealing dimensions invisible to the eye, thanks to algorithms leveraging years of research from Clarins laboratory. By combining AI, beauty tech with human touch, beauty consultations are enhanced."
Clarins group Chief Digital, IT & Business Support Officer, Laurent Malaveille: " We are very proud of the AI Skin Observer, the latest Beauty Tech release from our innovation lab, and excited by the enthusiastic feedback from both our beauty consultants and the first customers who tested this new service."
About Clarins
Founded in Paris in 1954 by Jacques Courtin, Clarins is a family-owned global beauty group that has been innovating for more than 70 years to advance responsible beauty. As a result of continuous research, its plant-based products — formulated and manufactured in France — are sold in over 150 countries through 20,000 points of sale. With nearly 95% of sales generated internationally, Clarins is the No. 1* premium skincare brand in Europe and a leading global player in beauty (skincare and make-up), spa, and wellness. The Group has also developed the brand myBlend, built on the concept of holistic beauty, combining targeted skincare, nutri-cosmetics, and beauty tech. Clarins counts more than 8,000 employees across its Paris headquarters, 28 subsidiaries worldwide, two R&D laboratories, and two industrial sites in France. The Group is jointly led by Jonathan Zrihen, President & CEO, together with Dr. Olivier Courtin and his niece Virginie Courtin, representing the second and third generations of the founding family. Guided by its raison d'être — "Making life more beautiful, passing on a more beautiful planet" — Clarins is committed to sustainable innovation, with over 80% of ingredients of natural origin and a wide range of initiatives to protect nature and care for people. https://www.groupeclarins.com/
*Source: NPD BeautyTrends®, Europe 5 (France, Germany, United Kingdom, Italy, Spain), luxury Skin Care market (products sold in perfumeries and department stores), value sales (€), for the period 3rd January 2022 to 1st January 2023.
Press contacts
France
Image Sept – Marie Artzner - Anne Auchatraire – Caroline Simon - clarins@image7.fr - +33 1 53 70 74 70
USA
Melissa Reidhead – melissa.reidhead@clarins.com and Lucas Petry – lucas.petry@clarins.com
UK
Shoshana Gillis – shoshana.gillis@clarins.com – +44 207 307 6792
China
Derek Hu – derek.hu@clarins.com – +86 186 0166 7400
Italy
Francesca Silva – Francesca.Silva@clarins.com and F.A Studio - f.andreuzzi@fa-studio.eu - c.gorla@fa-studio.eu
UAE
Jala Dia – Jala.Dia@clarins.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Clarins introduces the AI Skin Observer, in-store skin diagnosis augmenting human touch with the best of AI and Beauty Tech
Clarins introduces the AI Skin Observer, in-store skin diagnosis augmenting human touch with the best of AI and Beauty Tech
|
- CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine
- Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability
- Partnership aims to expand affordable and sustainable vaccine access in low- and middle-income countries
INCHEON, South Korea, Jan. 22, 2026 /PRNewswire/ -- SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI).
The announcement follows a funding agreement between CEPI and global pharmaceutical company MSD to support continued development of a Zaire ebolavirus vaccine. Under the agreement, CEPI will provide up to USD 30 million in funding to MSD, which will allocate the funding to its development partners, including SK bioscience and Hilleman Laboratories—a joint venture between MSD and Wellcome, a global charitable foundation focused on health research—to carry out key research, manufacturing process improvement and clinical development activities.
The collaboration builds on MSD's WHO-prequalified Zaire ebolavirus vaccine and focuses on updating the existing manufacturing process, which is complex and requires ultra-low temperature storage. These requirements pose logistical challenges in the remote, low-resource settings where Zaire ebolavirus outbreaks most often occur. By improving manufacturing yield and enhancing the thermostability of the vaccine, the project aims to support more affordable, accessible, and sustainable vaccine supply, subject to regulatory review and public health requirements.
Under the collaboration, Hilleman Laboratories —will lead the clinical development of the updated vaccine. SK bioscience, together with IDT Biologika, will develop the updated drug substance manufacturing process and the associated drug product. As a key implementation partner in the CEPI-backed public health initiative, SK bioscience will leverage its vaccine manufacturing expertise and infrastructure, as well as its collaboration with IDT Biologika. Through this role, the company aims to contribute to improving vaccine affordability, accessibility, and long-term sustainability in low- and middle-income countries.
Zaire ebolavirus is responsible for frequent and unpredictable Ebola outbreaks and is associated with a survival rate of around 50%. Recent outbreaks reported in parts of the Democratic Republic of the Congo and other countries have underscored the continued global risk posed by the virus, particularly in areas with limited healthcare access and logistics infrastructure.
Dr. Richard Hatchett, CEO of CEPI, said, "In a single decade the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks – and now CEPI's support will help to enable a sustainable and accessible supply of MSD's Zaire ebolavirus vaccine for years to come at a more affordable price. This deal brings together longstanding partners of CEPI with longstanding partners of MSD to boost global defences against one of the deadliest pathogens known to humankind, helping to save lives."
Jaeyong Ahn, CEO of SK bioscience, said, "Addressing deadly infectious diseases such as Ebola requires strong global collaboration. Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness."
SK bioscience has established a strong track record of collaboration with global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By leveraging its integrated capabilities across development, manufacturing, and supply, the company continues to expand its role as a global partner in public health–driven vaccine initiatives.
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
- SK bioscience Website
- SK bioscience Linkedin
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Muncheol. Kim (MC|_kim@sk.com)
- CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine
- Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability
- Partnership aims to expand affordable and sustainable vaccine access in low- and middle-income countries
INCHEON, South Korea, Jan. 22, 2026 /PRNewswire/ -- SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI).
The announcement follows a funding agreement between CEPI and global pharmaceutical company MSD to support continued development of a Zaire ebolavirus vaccine. Under the agreement, CEPI will provide up to USD 30 million in funding to MSD, which will allocate the funding to its development partners, including SK bioscience and Hilleman Laboratories—a joint venture between MSD and Wellcome, a global charitable foundation focused on health research—to carry out key research, manufacturing process improvement and clinical development activities.
The collaboration builds on MSD's WHO-prequalified Zaire ebolavirus vaccine and focuses on updating the existing manufacturing process, which is complex and requires ultra-low temperature storage. These requirements pose logistical challenges in the remote, low-resource settings where Zaire ebolavirus outbreaks most often occur. By improving manufacturing yield and enhancing the thermostability of the vaccine, the project aims to support more affordable, accessible, and sustainable vaccine supply, subject to regulatory review and public health requirements.
Under the collaboration, Hilleman Laboratories —will lead the clinical development of the updated vaccine. SK bioscience, together with IDT Biologika, will develop the updated drug substance manufacturing process and the associated drug product. As a key implementation partner in the CEPI-backed public health initiative, SK bioscience will leverage its vaccine manufacturing expertise and infrastructure, as well as its collaboration with IDT Biologika. Through this role, the company aims to contribute to improving vaccine affordability, accessibility, and long-term sustainability in low- and middle-income countries.
Zaire ebolavirus is responsible for frequent and unpredictable Ebola outbreaks and is associated with a survival rate of around 50%. Recent outbreaks reported in parts of the Democratic Republic of the Congo and other countries have underscored the continued global risk posed by the virus, particularly in areas with limited healthcare access and logistics infrastructure.
Dr. Richard Hatchett, CEO of CEPI, said, "In a single decade the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks – and now CEPI's support will help to enable a sustainable and accessible supply of MSD's Zaire ebolavirus vaccine for years to come at a more affordable price. This deal brings together longstanding partners of CEPI with longstanding partners of MSD to boost global defences against one of the deadliest pathogens known to humankind, helping to save lives."
Jaeyong Ahn, CEO of SK bioscience, said, "Addressing deadly infectious diseases such as Ebola requires strong global collaboration. Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness."
SK bioscience has established a strong track record of collaboration with global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By leveraging its integrated capabilities across development, manufacturing, and supply, the company continues to expand its role as a global partner in public health–driven vaccine initiatives.
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
- SK bioscience Website
- SK bioscience Linkedin
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Muncheol. Kim (MC|_kim@sk.com)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
